Use of Low-dose Zolpidem in Parkinson's Disease

Model scores of the 29,894 trials active now.

Model score 9% for any early termination, 4% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 14% of the time (453 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2020-01-24. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Sponsor's past termination rate: 0% (lowers risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Wording of the registration (title, summary, criteria) (lowers risk) · Wording Phrases that raised it: therapystageplaceboparkinsonscore
  Phrases that lowered it: evaluate theclinical trialparticipaterangewill evaluate
• Minimum age: 40 (lowers risk) · Who can join
• Phase: 2 (raises risk) · Design
• Blinding: quadruple (lowers risk) · Design
• Disease area, neurology: Yes (raises risk) · Disease area
• Disease area, cancer: No (lowers risk) · Disease area
• Drug's FAERS reports with a death: 12.8% (lowers risk) · Drug's FDA history
• Design: parallel (raises risk) · Design
• Has a data monitoring committee: Yes (raises risk) · Design
• Primary purpose: treatment (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 0 (raises risk) · Sponsor's track record
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Number of arms: 2 (raises risk) · Design
• Drug's FAERS reports before start: 90796 (lowers risk) · Drug's FDA history
• Drug's FAERS reports marked serious: 69.1% (lowers risk) · Drug's FDA history
• Drug's FAERS reports in the prior 12 months: 11860 (raises risk) · Drug's FDA history
• Maximum age: 80 (lowers risk) · Who can join
• Collaborators: 1 (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Study in Parkinson's Disease Patients With Dyskinesia With Combinations of JM-010 and Its Individual Components NCT04377945 · started 2021 · scored riskier than 52% of active trials terminated
• Efficacy and Safety of JM-010 in PD With Levodopa-Induced Dyskinesia NCT02439203 · started 2015 · scored riskier than 55% of active trials completed
• A Study in Parkinson's Disease in Patients With Moderate to Severe Dyskinesia NCT03956979 · started 2019 · scored riskier than 48% of active trials completed
• Influence of Piribedil (Clarium®) on Vigilance and Cognitive Function in Patients With Parkinson's Disease Compared to Other Non-Ergot Dopamine Agonists NCT01007864 · started 2010 · scored riskier than 36% of active trials completed
• Efficacy Phase IIa Study of CVXL-0107 in Advanced Parkinson's Disease NCT02641054 · started 2016 · scored riskier than 17% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.